Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

Vincent Y. Ng, MD
Published: Friday, Oct 25, 2019



Vincent Y. Ng, MD, an assistant professor of orthopedics at the University of Maryland Medical Center, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Most patients with high-risk soft tissue sarcoma present with early-stage disease, explains Ng. The primary tumor can often be treated with radiation and surgery in a majority of cases, according to Ng.

The main issue faced in high-risk soft tissue sarcoma is how to address micrometastatic disease, says Ng. Prior attempts with chemotherapy and targeted therapy have not provided dramatic improvement. Based on what has been seen in other cancer types and in preliminary research for soft tissue sarcoma, neoadjuvant immunotherapy may be a potential treatment for micrometastatic high-risk soft tissue sarcoma, concludes Ng.
SELECTED
LANGUAGE


Vincent Y. Ng, MD, an assistant professor of orthopedics at the University of Maryland Medical Center, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Most patients with high-risk soft tissue sarcoma present with early-stage disease, explains Ng. The primary tumor can often be treated with radiation and surgery in a majority of cases, according to Ng.

The main issue faced in high-risk soft tissue sarcoma is how to address micrometastatic disease, says Ng. Prior attempts with chemotherapy and targeted therapy have not provided dramatic improvement. Based on what has been seen in other cancer types and in preliminary research for soft tissue sarcoma, neoadjuvant immunotherapy may be a potential treatment for micrometastatic high-risk soft tissue sarcoma, concludes Ng.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x